{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:23:07Z","timestamp":1792610587733,"version":"4.5.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the association between radiotherapy and the risk of second malignant neoplasm (SMN) development among patients with bladder cancer (BC). Overall survival (OS) is compared among patients developing SMN and without.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We identified patients diagnosed with BC from the Surveillance, Epidemiology, and End Results (SEER) database. The development of an SMN is defined as any SMN occurring more than 5 years after the diagnosis of BC. The Fine-Gray competing risk regression is used to estimate the probability of SMN. The radiotherapy-associated risk (RR) for SMNs is assessed by Poisson regression. The Kaplan\u2013Meier method was used to evaluate the OS of patients with SMNs. Propensity score matching (PSM) is performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 76575 BC patients are enrolled in our study. The probability of SMNs in the radiotherapy cohort is statistically higher than in the non-radiotherapy cohort. In competing risk regression analysis, radiotherapy is proven to be associated with a higher risk of SMN (Hazard ratio: 1.23; 95% CI: 1.102\u20131.368). The radiotherapy-associated risks significantly increase in the radiotherapy cohort (RR: 1.28; 95% CI: 1.14\u20131.43). In site-specific analysis, statistically significant results are observed in lung and bronchus (LAB) cancer and hematological malignancies. The OS rate in patients developing SMN is significantly lower than that among matched patients with primary BC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Radiotherapy for BC is associated with SMN. Radiotherapy increases the risk of secondary low-dose area cancer development, including LAB cancer or hematological malignancies. Notably, this effect is not observed in the high-dose area involving pelvic tumors. Patients developing SMN showed poorer OS.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.953615","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T07:11:33Z","timestamp":1668582693000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk and prognosis of secondary malignant neoplasms after radiation therapy for bladder cancer: A large population-based cohort study"],"prefix":"10.3389","volume":"12","author":[{"given":"Ru","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangpeng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-019-0199-x","article-title":"Organ preservation in bladder cancer: an opportunity for truly personalized treatment","volume":"16","author":"Song","year":"2019","journal-title":"Nat Rev Urol."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.04.006","article-title":"Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials","volume":"95","author":"Arcangeli","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/cancers13010087","article-title":"Review of experimental studies to improve radiotherapy response in bladder cancer: Comments and perspectives","volume":"13","author":"Silina","year":"2021","journal-title":"Cancers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.584072","article-title":"Risk and prognosis of secondary rectal cancer after radiation therapy for pelvic cancer","volume":"10","author":"Yang","year":"2020","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.31661","article-title":"Association of radiotherapy for rectal cancer and second gynecological malignant neoplasms","volume":"4","author":"Guan","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.586401","article-title":"Risk and prognosis of secondary bladder cancer after radiation therapy for rectal cancer: A Large population-based cohort study","volume":"10","author":"Guan","year":"2020","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.034","article-title":"External beam radiotherapy increases the risk of bladder cancer when compared with radical prostatectomy in patients affected by prostate cancer: A population-based analysis","volume":"75","author":"Moschini","year":"2019","journal-title":"Eur Urol."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21631","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1667\/RR0763.1","article-title":"Solid cancer incidence in atomic bomb survivors: 1958-1998","volume":"168","author":"Preston","year":"2007","journal-title":"Radiat Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26240","article-title":"The cancer burden in the united kingdom in 2007 due to radiotherapy","volume":"129","author":"Maddams","year":"2011","journal-title":"Int J Cancer."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph9124744","article-title":"Second malignant neoplasms following radiotherapy","volume":"9","author":"Kumar","year":"2012","journal-title":"Int J Environ Res Public Health"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr533","article-title":"Second malignant neoplasms and cardiovascular disease following radiotherapy","volume":"104","author":"Travis","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70061-4","article-title":"Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries","volume":"12","author":"de Gonzalez","year":"2011","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3069","article-title":"Assessing the risk of second malignancies after modern radiotherapy","volume":"11","author":"Newhauser","year":"2011","journal-title":"Nat Rev Cancer."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010580","article-title":"Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer","volume":"345","author":"Kapiteijn","year":"2001","journal-title":"New Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60484-0","article-title":"Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial","volume":"373","author":"Sebag-Montefiore","year":"2009","journal-title":"Lancet (London England)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41591-020-01195-4","article-title":"Targeting metastatic cancer","volume":"27","author":"Ganesh","year":"2021","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12032-020-01447-w","article-title":"Steps in metastasis: an updated review","volume":"38","author":"Majidpoor","year":"2021","journal-title":"Med Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2017.02.007","article-title":"Secondary malignancies after rectal cancer resection with and without radiation therapy: A propensity-adjusted, population-based SEER analysis","volume":"123","author":"Warschkow","year":"2017","journal-title":"Radiother Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i33.4850","article-title":"Neoadjuvant radiotherapy for rectal cancer management","volume":"25","author":"Feeney","year":"2019","journal-title":"World J Gastroenterol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2017.82","article-title":"Landmarks in the treatment of muscle-invasive bladder cancer","volume":"14","author":"Lobo","year":"2017","journal-title":"Nat Rev Urol."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.527121","article-title":"Pre-clinical research on bladder toxicity after radiotherapy for pelvic cancers: State-of-the art and challenges","volume":"10","author":"Zuppone","year":"2020","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.953615\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T07:11:34Z","timestamp":1668582694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.953615\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":22,"alternative-id":["10.3389\/fonc.2022.953615"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.953615","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]},"article-number":"953615"}}